Previous 10 | Next 10 |
home / stock / anpcf / anpcf news
Brett Swansiger joins as Chief Commercial Officer Karen Miller PhD joins as Chief Scientific Officer GUILDFORD, SURREY / ACCESSWIRE / June 5, 2023 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce the appointments of Br...
Pharma Services Contract Win Parsortix DNA Damage Response Assays developed by ANGLE to be used for exploratory objectives in a Phase 1 clinical trial Trial expected to complete by year end 2024 GUILDFORD, SURREY / ACCESSWIRE / May 25, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a worl...
GUILDFORD, SURREY / ACCESSWIRE / May 22, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company announces that Garth Selvey has informed the Board of his intention to retire and leave ANGLE at the publication of the 2023 Interims in September. Garth will hand over the Cha...
Preliminary Results for the year ended 31 December 2022 FDA CLEARANCE A MAJOR BREAKTHROUGH FOR PARSORTIX LIQUID BIOPS Parsortix system substantially out-performs standard of care for ovarian cancer diagnosis Prostate cancer partnership signed with Solaris Health Pipeline of op...
(NewsDirect) ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Thomas Warner from Proactive after announcing a development partnership with BioView. The partnership will see the two firms develop to create a circulating tumour cell (CTC) HER2 assay for breast cance...
PARSORTIX POSTER PRESENTED AT AACR ANNUAL MEETING 2023 Study demonstrates the feasibility of combining IF and HER2 FISH analysis with CTCs harvested using the Parsortix system Capability to measure HER2 protein overexpression on CTCs using ANGLE's Portrait Flex assay opens up substantia...
Notice of Preliminary Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / April 3, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2022 on Friday 21 April 2023. A virtual meeting and we...
GUILDFORD, UK / ACCESSWIRE / March 10, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at the Annual General Meeting on 30 June 2021 ("the Remuneration Policy"), the Remuneration Committee ...
Director/PDMR shareholding GUILDFORD, SURREY / ACCESSWIRE / February 9, 2023 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, on 09 February 2023, it has been notified that Andrew Newland, Chief Executive Officer, purchased 125,000 or...
Joseph Eid M.D., is a US certified medical oncologist with extensive experience of the use of biomarkers in clinical trials and as companion diagnostics Previous roles include senior positions in oncology at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche GUILDFORD, SURREY / A...
News, Short Squeeze, Breakout and More Instantly...
GUILDFORD, SURREY / ACCESSWIRE / July 12, 2024 / TR-1: Standard form for notification of major holdings This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the Un...
GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report a...